Free Trial

Faron Pharmaceuticals Oy (FARN) Competitors

Faron Pharmaceuticals Oy logo
GBX 172.70 -4.80 (-2.70%)
As of 04:07 AM Eastern

FARN vs. ERGO, SLN, PRTC, HZD, AVCT, VRP, ARIX, CIR, BVXP, and 4BB

Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

Faron Pharmaceuticals Oy vs. Its Competitors

Faron Pharmaceuticals Oy (LON:FARN) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

2.9% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 4.1% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Faron Pharmaceuticals Oy has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 0.46% -70.00%
Ergomed 9.87%18.08%10.16%

Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£0.27-639.63
Ergomed£152.09M0.00£15M£0.29N/A

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Ergomed. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Ergomed Neutral

Summary

Ergomed beats Faron Pharmaceuticals Oy on 10 of the 11 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FARN vs. The Competition

MetricFaron Pharmaceuticals OyBiotechnology IndustryMedical SectorLON Exchange
Market Cap£193.35M£223.11M£6.04B£2.60B
Dividend YieldN/A3.81%5.73%5.32%
P/E Ratio-639.6399.6485.104,425.56
Price / SalesN/A5,775.70556.60101,390.64
Price / Cash20.0013.1937.5727.90
Price / Book0.0999.4912.347.72
Net Income-£60.23M-£90.99M£3.32B£5.89B
7 Day Performance1.53%-0.93%-1.33%0.26%
1 Month Performance-11.44%4.24%8.12%2.15%
1 Year Performance-14.50%688.51%73.80%142.49%

Faron Pharmaceuticals Oy Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FARN
Faron Pharmaceuticals Oy
N/AGBX 172.70
-2.7%
N/A-14.6%£193.35MN/A-639.6334News Coverage
Positive News
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
N/AGBX 134
-0.6%
GBX 455
+239.6%
-13.8%£323.86M£6.17M788.24300
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
AVCT
Avacta Group
2.3997 of 5 stars
GBX 71.36
-0.9%
GBX 99
+38.7%
+6.3%£291.32M£113K-406.58120News Coverage
Analyst Forecast
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,425
+1.0%
N/A-38.9%£126.71M£13.66M1,637.1912High Trading Volume
4BB
4basebio
1.4857 of 5 stars
GBX 764.45
-1.4%
GBX 1,600
+109.3%
-46.4%£118.38M£1.78M-772.17101

Related Companies and Tools


This page (LON:FARN) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners